IrelandIreland

Gene variant may increase severity of multiple sclerosis

03.08.2010

Dublin/St. Paul – Irish researchers have reported that a specific gene variant may increase the severity of multiple sclerosis (MS) symptoms. For the study, which was published in Neurology (3rd August), the research team led by Margaret O'Brien from St. Vincent's University Hospital in Dublin screened the oligoadenylate synthetase gene (OAS1) in 401 MS patients, 394 individuals without MS, and 178 MS patients receiving the drug beta interferon. Following the analysis of the OAS1 gene, they found that 63 percent of those with MS had the AA genotype, compared to 57 percent of those without MS. The GG genotype was found in 37 percent of MS patients, compared to 43 percent of those without the disease. While the OAS1 gene was weakly associated with disease susceptibility, the study found that people carrying the AA genotype suffered earlier relapses and increased disease activity compared to those without the genotype. The study also found that individuals carrying the GG genotype exhibited lower levels of disease activity and experienced fewer relapses. "It's possible that the GG genotype may protect against increased disease activity in people with MS, but more research is needed," said O'Brien.

IrelandIreland

20.03.2012

While on a trip to strengthen economic ties between Ireland and California, Ireland's minister for jobs, enterprise and innovation, Richard Bruton, revealed on 15 March that two Irish government organisations have provided...

IrelandIreland

16.03.2012

Dublin – Irish drugmaker Shire plc has agreed to pay US-$100m in upfront for Ferrokin Biosciences Inc., a San Francisco-based specialist for iron chelation therapies. US-$225m could be added if certain milestones are achieved....

IrelandIreland

07.03.2012

Abbott Laboratories is to spend a85m and expand its pharmaceutical manu­facturing facility in Sligo (Ireland), saying that would help the company to ensure its supply of compounds in bio­pharmaceutical areas like virology and...

IrelandIreland

24.01.2012

Weston/Dublin - The focus for Tysabri, the MS drug jointly developed by Irish Elan and US-Biogen, has become a little more accurate. The US Food and Drug Administration (FDA) stated that the occurrence of antibodies against the...

IrelandIreland

13.12.2011

Dublin/Cambridge – The University of Cambridge and Irish drugmaker Elan Pharmaceutical Inc. have joined forces in the battle against Alzheimer’s Disease. Together, the two will create the Cambridge-Elan Centre for Research...

IrelandIreland

07.12.2011

Uppsala/Craigavon - Irish Almac trusts a Swedish platform to develop new cancer drug candidates. As Uppsala-based Beactica announced on Tuesday, its Sprint-technology will be used to identify fragment hits against a number of...

IrelandIreland

05.12.2011

Dublin /New York – Irish Tibotec Pharmaceutical Ltd and Bristol-Myers Squibb (BMS) have entered into a clinical collaboration for the treatment of chronic hepatitis C infections with a combination of BMS’ NS5A replication complex...

IrelandIreland

01.10.2011

Athlone – Biopharma group Alkermes has established its new Irish corporate base following its merger with Elan Drug Tech­nologies. The a712m (US$960m) deal agreed back in May – which saw Alkermes acquire Elan’s Athlone-based drug...

Displaying results 1 to 10 out of 49

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive-ireland/article/gene-variant-may-increase-severity-of-multiple-sclerosis.html

Events

All Events

Stock list

All quotes

TOP

  • ADDEX3.30 CHF6.45%
  • PAION3.17 EUR3.93%
  • SANTHERA90.75 CHF3.07%

FLOP

  • WILEX2.36 EUR-12.27%
  • THERAMETRICS0.08 CHF-11.11%
  • CYTOS0.23 CHF-4.17%

TOP

  • CO.DON3.27 EUR30.8%
  • PAION3.17 EUR27.8%
  • EPIGENOMICS3.80 EUR22.6%

FLOP

  • MEDIGENE3.82 EUR-17.8%
  • ADDEX3.30 CHF-17.5%
  • EVOTEC3.10 EUR-15.5%

TOP

  • SANTHERA90.75 CHF2124.3%
  • CO.DON3.27 EUR280.2%
  • PAION3.17 EUR213.9%

FLOP

  • CYTOS0.23 CHF-94.3%
  • THERAMETRICS0.08 CHF-42.9%
  • BIOFRONTERA2.18 EUR-40.3%

No liability assumed, Date: 21.09.2014


Current issue

All issues

Product of the week

Products